Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 354

1.

Correlation of PD-L1 expression with tumor mutation burden and gene signatures for prognosis in early stage squamous cell lung carcinoma.

Yu H, Chen Z, Ballman K, Watson MA, Govindan R, Lanc I, Beer DG, Bueno R, Chirieac L, Chui MH, Chen G, Franklin WA, Gandara DR, Genova C, Brovsky K, Harpole D, Joshi M, Merrick DT, Richards W, Rivard CJ, Tsao MS, van Bokhoven A, Shepherd FA, Hirsch FR.

J Thorac Oncol. 2018 Sep 22. pii: S1556-0864(18)33116-2. doi: 10.1016/j.jtho.2018.09.006. [Epub ahead of print]

PMID:
30253973
2.

American Society of Clinical Oncology's Global Oncology Leadership Task Force: Findings and Actions.

Hortobagyi GN, Pyle D, Cazap EL, El Saghir NS, Shulman LN, Lyman GH, Schnipper LE, Adebamowo CA, Gandara DR, Vose J, Wong SL, Yu P.

J Glob Oncol. 2018 Sep;(4):1-8. doi: 10.1200/JGO.17.00060. Epub 2017 Aug 11.

PMID:
30241187
3.

Atezolizumab Treatment Beyond Progression in Advanced Non-Small Cell Lung Cancer: Results From the Randomized, Phase III OAK Study.

Gandara DR, von Pawel J, Mazieres J, Sullivan R, Helland Å, Han JY, Aix SP, Rittmeyer A, Barlesi F, Kubo T, Park K, Goldschmidt J, Gandhi M, Yun C, Yu W, Matheny C, He P, Sandler A, Ballinger M, Fehrenbacher L.

J Thorac Oncol. 2018 Sep 11. pii: S1556-0864(18)33043-0. doi: 10.1016/j.jtho.2018.08.2027. [Epub ahead of print]

PMID:
30217492
4.

A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors.

Liu SV, Groshen SG, Kelly K, Reckamp KL, Belani C, Synold TW, Goldkorn A, Gitlitz BJ, Cristea MC, Gong IY, Semrad TJ, Xu Y, Xu T, Koczywas M, Gandara DR, Newman EM.

Cancer Chemother Pharmacol. 2018 Oct;82(4):723-732. doi: 10.1007/s00280-018-3672-y. Epub 2018 Aug 20.

PMID:
30128950
5.

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab.

Gandara DR, Paul SM, Kowanetz M, Schleifman E, Zou W, Li Y, Rittmeyer A, Fehrenbacher L, Otto G, Malboeuf C, Lieber DS, Lipson D, Silterra J, Amler L, Riehl T, Cummings CA, Hegde PS, Sandler A, Ballinger M, Fabrizio D, Mok T, Shames DS.

Nat Med. 2018 Sep;24(9):1441-1448. doi: 10.1038/s41591-018-0134-3. Epub 2018 Aug 6.

PMID:
30082870
6.

Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC.

Riess JW, Gandara DR, Frampton GM, Madison R, Peled N, Bufill JA, Dy GK, Ou SI, Stephens PJ, McPherson JD, Lara PN Jr, Burich RA, Ross JS, Miller VA, Ali SM, Mack PC, Schrock AB.

J Thorac Oncol. 2018 Oct;13(10):1560-1568. doi: 10.1016/j.jtho.2018.06.019. Epub 2018 Jul 5.

PMID:
29981927
7.

In Search of an Oncogene Driver for Squamous Lung Cancer.

Gandara DR, Riess JW, Lara PN Jr.

JAMA Oncol. 2018 Sep 1;4(9):1197-1198. doi: 10.1001/jamaoncol.2018.0774. No abstract available.

PMID:
29902311
8.

Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC.

Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, Herbst RS, Mok TS, Peled N, Pirker R, Raez LE, Reck M, Riess JW, Sequist LV, Shepherd FA, Sholl LM, Tan DSW, Wakelee HA, Wistuba II, Wynes MW, Carbone DP, Hirsch FR, Gandara DR.

J Thorac Oncol. 2018 Sep;13(9):1248-1268. doi: 10.1016/j.jtho.2018.05.030. Epub 2018 Jun 6. Review.

PMID:
29885479
9.

CT perfusion imaging of lung cancer: benefit of motion correction for blood flow estimates.

Chu LL, Knebel RJ, Shay AD, Santos J, Badawi RD, Gandara DR, Knollmann FD.

Eur Radiol. 2018 Jun 4. doi: 10.1007/s00330-018-5492-1. [Epub ahead of print]

PMID:
29869174
10.

Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer.

Fehrenbacher L, von Pawel J, Park K, Rittmeyer A, Gandara DR, Ponce Aix S, Han JY, Gadgeel SM, Hida T, Cortinovis DL, Cobo M, Kowalski DM, De Marinis F, Gandhi M, Danner B, Matheny C, Kowanetz M, He P, Felizzi F, Patel H, Sandler A, Ballinger M, Barlesi F.

J Thorac Oncol. 2018 Aug;13(8):1156-1170. doi: 10.1016/j.jtho.2018.04.039. Epub 2018 May 17.

PMID:
29777823
11.

The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.

Zill OA, Banks KC, Fairclough SR, Mortimer SA, Vowles JV, Mokhtari R, Gandara DR, Mack PC, Odegaard JI, Nagy RJ, Baca AM, Eltoukhy H, Chudova DI, Lanman RB, Talasaz A.

Clin Cancer Res. 2018 Aug 1;24(15):3528-3538. doi: 10.1158/1078-0432.CCR-17-3837. Epub 2018 May 18.

PMID:
29776953
12.

A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma.

El-Khoueiry AB, O'Donnell R, Semrad TJ, Mack P, Blanchard S, Bahary N, Jiang Y, Yen Y, Wright J, Chen H, Lenz HJ, Gandara DR.

Cancer Chemother Pharmacol. 2018 May;81(5):957-963. doi: 10.1007/s00280-018-3553-4. Epub 2018 Mar 8.

PMID:
29520435
13.

Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions.

Floc'h N, Martin MJ, Riess JW, Orme JP, Staniszewska AD, Ménard L, Cuomo ME, O'Neill DJ, Ward RA, Finlay MRV, McKerrecher D, Cheng M, Vang DP, Burich RA, Keck JG, Gandara DR, Mack PC, Cross DAE.

Mol Cancer Ther. 2018 May;17(5):885-896. doi: 10.1158/1535-7163.MCT-17-0758. Epub 2018 Feb 26.

PMID:
29483211
14.

Smoking, Sex, and Non-Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424).

Cheng TD, Darke AK, Redman MW, Zirpoli GR, Davis W, Payne Ondracek R, Bshara W, Omilian AR, Kratzke R, Reid ME, Molina JR, Kolesar JM, Chen Y, MacRae RM, Moon J, Mack P, Gandara DR, Kelly K, Santella RM, Albain KS, Ambrosone CB.

J Natl Cancer Inst. 2018 Jul 1;110(7):734-742. doi: 10.1093/jnci/djx260.

PMID:
29346580
15.

Clinical predictors of survival in young patients with small cell lung cancer: Results from the California Cancer Registry.

Lara JD, Brunson A, Riess JW, Kelly K, Lara PN Jr, Gandara DR.

Lung Cancer. 2017 Oct;112:165-168. doi: 10.1016/j.lungcan.2017.08.015. Epub 2017 Aug 31.

PMID:
29191590
16.

Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.

Herbst RS, Redman MW, Kim ES, Semrad TJ, Bazhenova L, Masters G, Oettel K, Guaglianone P, Reynolds C, Karnad A, Arnold SM, Varella-Garcia M, Moon J, Mack PC, Blanke CD, Hirsch FR, Kelly K, Gandara DR.

Lancet Oncol. 2018 Jan;19(1):101-114. doi: 10.1016/S1470-2045(17)30694-0. Epub 2017 Nov 20.

17.

Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial.

Wakelee HA, Dahlberg SE, Keller SM, Tester WJ, Gandara DR, Graziano SL, Adjei AA, Leighl NB, Aisner SC, Rothman JM, Patel JD, Sborov MD, McDermott SR, Perez-Soler R, Traynor AM, Butts C, Evans T, Shafqat A, Chapman AE, Kasbari SS, Horn L, Ramalingam SS, Schiller JH; ECOG-ACRIN.

Lancet Oncol. 2017 Dec;18(12):1610-1623. doi: 10.1016/S1470-2045(17)30691-5. Epub 2017 Nov 9.

PMID:
29129443
18.

Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.

Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, McGranahan N, Wilson GA, Birkbak NJ, Olivas VR, Rotow J, Maynard A, Wang V, Gubens MA, Banks KC, Lanman RB, Caulin AF, St John J, Cordero AR, Giannikopoulos P, Simmons AD, Mack PC, Gandara DR, Husain H, Doebele RC, Riess JW, Diehn M, Swanton C, Bivona TG.

Nat Genet. 2017 Dec;49(12):1693-1704. doi: 10.1038/ng.3990. Epub 2017 Nov 6.

19.

Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials.

West HL, Moon J, Wozniak AJ, Mack P, Hirsch FR, Bury MJ, Kwong M, Nguyen DD, Moore DF, Miao J, Redman M, Kelly K, Gandara DR.

Clin Lung Cancer. 2018 Jan;19(1):84-92. doi: 10.1016/j.cllc.2017.06.016. Epub 2017 Jul 6.

20.

Double Trouble: A Case Series on Concomitant Genetic Aberrations in NSCLC.

Van Der Steen N, Mentens Y, Ramael M, Leon LG, Germonpré P, Ferri J, Gandara DR, Giovannetti E, Peters GJ, Pauwels P, Rolfo C.

Clin Lung Cancer. 2018 Jan;19(1):35-41. doi: 10.1016/j.cllc.2017.06.010. Epub 2017 Jul 6. Review.

PMID:
28757336
21.

Phase II Study of Dovitinib in Patients Progressing on Anti-Vascular Endothelial Growth Factor Therapy.

Semrad TJ, Kim EJ, Tanaka MS, Sands J, Roberts C, Burich RA, Li Y, Gandara DR, Lara P Jr, Mack PC.

Cancer Treat Res Commun. 2017;10:21-26. doi: 10.1016/j.ctarc.2016.12.002.

22.

An Evolving Algorithm to Select and Sequence Therapies in EGFR Mutation-positive NSCLC: A Strategic Approach.

Melosky B, Popat S, Gandara DR.

Clin Lung Cancer. 2018 Jan;19(1):42-50. doi: 10.1016/j.cllc.2017.05.019. Epub 2017 Jun 8.

PMID:
28668205
23.

Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905).

Tsao AS, Moon J, Wistuba II, Vogelzang NJ, Kalemkerian GP, Redman MW, Gandara DR, Kelly K.

J Thorac Oncol. 2017 Aug;12(8):1299-1308. doi: 10.1016/j.jtho.2017.05.021. Epub 2017 Jun 6.

24.

Scientific Advances in Thoracic Oncology 2016.

Soo RA, Stone ECA, Cummings KM, Jett JR, Field JK, Groen HJM, Mulshine JL, Yatabe Y, Bubendorf L, Dacic S, Rami-Porta R, Detterbeck FC, Lim E, Asamura H, Donington J, Wakelee HA, Wu YL, Higgins K, Senan S, Solomon B, Kim DW, Johnson M, Yang JCH, Sequist LV, Shaw AT, Ahn MJ, Costa DB, Patel JD, Horn L, Gettinger S, Peters S, Wynes MW, Faivre-Finn C, Rudin CM, Tsao A, Baas P, Kelly RJ, Leighl NB, Scagliotti GV, Gandara DR, Hirsch FR, Spigel DR.

J Thorac Oncol. 2017 Aug;12(8):1183-1209. doi: 10.1016/j.jtho.2017.05.019. Epub 2017 Jun 1. Review.

25.

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, Remon-Masip J, Janne PA, Awad MM, Peled N, Byoung CC, Karp DD, Van Den Heuvel M, Wakelee HA, Neal JW, Mok TSK, Yang JCH, Ou SI, Pall G, Froesch P, Zalcman G, Gandara DR, Riess JW, Velcheti V, Zeidler K, Diebold J, Früh M, Michels S, Monnet I, Popat S, Rosell R, Karachaliou N, Rothschild SI, Shih JY, Warth A, Muley T, Cabillic F, Mazières J, Drilon A.

J Clin Oncol. 2017 May 1;35(13):1403-1410. doi: 10.1200/JCO.2016.70.9352. Epub 2017 Mar 13.

26.

Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083.

Somlo G, Frankel PH, Arun BK, Ma CX, Garcia AA, Cigler T, Cream LV, Harvey HA, Sparano JA, Nanda R, Chew HK, Moynihan TJ, Vahdat LT, Goetz MP, Beumer JH, Hurria A, Mortimer J, Piekarz R, Sand S, Herzog J, Van Tongeren LR, Ferry-Galow KV, Chen AP, Ruel C, Newman EM, Gandara DR, Weitzel JN.

Clin Cancer Res. 2017 Aug 1;23(15):4066-4076. doi: 10.1158/1078-0432.CCR-16-2714. Epub 2017 Mar 29.

27.

Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non-Small-cell Lung Cancer.

Gandara DR, Riess JW, Kelly K, Li T, Mack PC, Lara PN Jr.

Clin Lung Cancer. 2017 Jan;18(1):1-4. doi: 10.1016/j.cllc.2016.12.011. Epub 2016 Dec 24.

PMID:
28082049
28.

Integrated Metabolomics and Proteomics Highlight Altered Nicotinamide- and Polyamine Pathways in Lung Adenocarcinoma.

Fahrmann JF, Grapov DD, Wanichthanarak K, DeFelice BC, Salemi MR, Rom WN, Gandara DR, Phinney BS, Fiehn O, Pass H, Miyamoto S.

Carcinogenesis. 2017 Jan 3. pii: bgw205. doi: 10.1093/carcin/bgw205. [Epub ahead of print] Review.

29.

Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung Cancer.

Lara MS, Holland WS, Chinn D, Burich RA, Lara PN Jr, Gandara DR, Kelly K, Mack PC.

Clin Lung Cancer. 2017 May;18(3):281-285. doi: 10.1016/j.cllc.2016.11.006. Epub 2016 Nov 21.

30.

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera OA, De Marinis F, Turna H, Lee JS, Ballinger M, Kowanetz M, He P, Chen DS, Sandler A, Gandara DR; OAK Study Group.

Lancet. 2017 Jan 21;389(10066):255-265. doi: 10.1016/S0140-6736(16)32517-X. Epub 2016 Dec 13. Erratum in: Lancet. 2017 Apr 8;389(10077):e5.

PMID:
27979383
31.

Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer.

Li T, Piperdi B, Walsh WV, Kim M, Beckett LA, Gucalp R, Haigentz M Jr, Bathini VG, Wen H, Zhou K, Pasquinelli PB, Gajavelli S, Sreedhara M, Xie X, Lara PN Jr, Gandara DR, Perez-Soler R.

Clin Lung Cancer. 2017 Jan;18(1):60-67. doi: 10.1016/j.cllc.2016.10.003. Epub 2016 Oct 28.

32.

A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer.

Gandara DR, Leighl N, Delord JP, Barlesi F, Bennouna J, Zalcman G, Infante JR, Reckamp KL, Kelly K, Shepherd FA, Mazieres J, Janku F, Gardner OS, Mookerjee B, Wu Y, Cox DS, Schramek D, Peddareddigari V, Liu Y, D'Amelio AM Jr, Blumenschein G Jr.

J Thorac Oncol. 2017 Mar;12(3):556-566. doi: 10.1016/j.jtho.2016.11.2218. Epub 2016 Nov 19.

33.

Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma.

Cho H, Matsumoto S, Fujita Y, Kuroda A, Menju T, Sonobe M, Kondo N, Torii I, Nakano T, Lara PN, Gandara DR, Date H, Hasegawa S.

J Thorac Oncol. 2017 Mar;12(3):477-490. doi: 10.1016/j.jtho.2016.10.023. Epub 2016 Nov 17. Erratum in: J Thorac Oncol. 2017 May;12 (5):900.

34.

Proteomic profiling of lung adenocarcinoma indicates heightened DNA repair, antioxidant mechanisms and identifies LASP1 as a potential negative predictor of survival.

Fahrmann JF, Grapov D, Phinney BS, Stroble C, DeFelice BC, Rom W, Gandara DR, Zhang Y, Fiehn O, Pass H, Miyamoto S.

Clin Proteomics. 2016 Oct 27;13:31. doi: 10.1186/s12014-016-9132-y. eCollection 2016.

35.

O.02: Plasma Next Generation Sequencing of Over 5,000 Advanced Non-Small Cell Lung Cancer Patients With Clinical Correlations.

Mack PC, Banks KC, Zill OA, Mortimer SA, Chudova DI, Odegaard J, Lee CE, Nagy RJ, Eltoukhy H, Talasaz A, Lanman R, Gandara DR.

J Thorac Oncol. 2016 Oct;11(10S):S168-S169. doi: 10.1016/j.jtho.2016.08.005. Epub 2016 Sep 22. No abstract available.

36.

A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study.

Kirschbaum MH, Frankel P, Synold TW, Zain J, Claxton D, Tuscano J, Newman EM, Gandara DR, Lara PN Jr.

Br J Haematol. 2018 Feb;180(3):445-448. doi: 10.1111/bjh.14333. Epub 2016 Sep 21. No abstract available.

PMID:
27650362
37.

Theory Meets Practice for Immune Checkpoint Blockade in Small-Cell Lung Cancer.

Riess JW, Lara PN Jr, Gandara DR.

J Clin Oncol. 2016 Nov 1;34(31):3717-3718. doi: 10.1200/JCO.2016.69.0040. No abstract available.

38.

Overview of Thoracic Oncology Trials in Cooperative Groups Around the Globe.

Salahudeen AA, Patel MI, Baas P, Curran WJ, Bradley JD, Gandara DR, Goss GD, Mok TS, Ramalingam SS, Vokes EE, Malik SM, Wakelee HA.

Clin Lung Cancer. 2017 Jan;18(1):5-12. doi: 10.1016/j.cllc.2016.06.007. Epub 2016 Jun 27. Review.

39.

Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non-Small-Cell Lung Cancer.

Hirsch FR, Govindan R, Zvirbule Z, Braiteh F, Rittmeyer A, Belda-Iniesta C, Isla D, Cosgriff T, Boyer M, Ueda M, Phan S, Gandara DR.

Clin Lung Cancer. 2017 Jan;18(1):43-49. doi: 10.1016/j.cllc.2016.05.011. Epub 2016 Jun 4.

PMID:
27461773
40.

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016.

Tan DS, Yom SS, Tsao MS, Pass HI, Kelly K, Peled N, Yung RC, Wistuba II, Yatabe Y, Unger M, Mack PC, Wynes MW, Mitsudomi T, Weder W, Yankelevitz D, Herbst RS, Gandara DR, Carbone DP, Bunn PA Jr, Mok TS, Hirsch FR.

J Thorac Oncol. 2016 Jul;11(7):946-63. doi: 10.1016/j.jtho.2016.05.008. Epub 2016 May 23. Review.

41.

Scientific Advances in Lung Cancer 2015.

Tsao AS, Scagliotti GV, Bunn PA Jr, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS, Adusumilli PS, Rami-Porta R, Asamura H, Van Schil PE, Darling GE, Ramalingam SS, Gomez DR, Rosenzweig KE, Zimmermann S, Peters S, Ignatius Ou SH, Reungwetwattana T, Jänne PA, Mok TS, Wakelee HA, Pirker R, Mazières J, Brahmer JR, Zhou Y, Herbst RS, Papadimitrakopoulou VA, Redman MW, Wynes MW, Gandara DR, Kelly RJ, Hirsch FR, Pass HI.

J Thorac Oncol. 2016 May;11(5):613-638. doi: 10.1016/j.jtho.2016.03.012. Epub 2016 Mar 22. Review.

42.

Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer.

Kummar S, Wade JL, Oza AM, Sullivan D, Chen AP, Gandara DR, Ji J, Kinders RJ, Wang L, Allen D, Coyne GO, Steinberg SM, Doroshow JH.

Invest New Drugs. 2016 Jun;34(3):355-63. doi: 10.1007/s10637-016-0335-x. Epub 2016 Mar 21.

43.

Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

Bunn PA Jr, Minna JD, Augustyn A, Gazdar AF, Ouadah Y, Krasnow MA, Berns A, Brambilla E, Rekhtman N, Massion PP, Niederst M, Peifer M, Yokota J, Govindan R, Poirier JT, Byers LA, Wynes MW, McFadden DG, MacPherson D, Hann CL, Farago AF, Dive C, Teicher BA, Peacock CD, Johnson JE, Cobb MH, Wendel HG, Spigel D, Sage J, Yang P, Pietanza MC, Krug LM, Heymach J, Ujhazy P, Zhou C, Goto K, Dowlati A, Christensen CL, Park K, Einhorn LH, Edelman MJ, Giaccone G, Gerber DE, Salgia R, Owonikoko T, Malik S, Karachaliou N, Gandara DR, Slotman BJ, Blackhall F, Goss G, Thomas R, Rudin CM, Hirsch FR.

J Thorac Oncol. 2016 Apr;11(4):453-74. doi: 10.1016/j.jtho.2016.01.012. Epub 2016 Jan 30. Review. No abstract available.

44.

SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay.

Lara PN Jr, Moon J, Hesketh PJ, Redman MW, Williamson SK, Akerley WL 3rd, Hirsch FR, Mack PC, Gandara DR.

J Thorac Oncol. 2016 Mar;11(3):420-5. doi: 10.1016/j.jtho.2015.11.003. Epub 2015 Dec 25.

45.

Postprogression Prolongation of Survival in EGFR-Mutated Lung Cancer: Reconciling the ASPIRATION and IMPRESS Trials.

Gandara DR, Redman M, Hirsch FR.

JAMA Oncol. 2016 Mar;2(3):300-1. doi: 10.1001/jamaoncol.2015.4920. No abstract available.

PMID:
26720042
46.

ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.

Govindan R, Mandrekar SJ, Gerber DE, Oxnard GR, Dahlberg SE, Chaft J, Malik S, Mooney M, Abrams JS, Jänne PA, Gandara DR, Ramalingam SS, Vokes EE.

Clin Cancer Res. 2015 Dec 15;21(24):5439-44. doi: 10.1158/1078-0432.CCR-15-0354. Review.

47.

Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database.

Lara PN Jr, Moon J, Redman MW, Semrad TJ, Kelly K, Allen J, Gitlitz B, Mack PC, Gandara DR.

Clin Lung Cancer. 2016 Mar;17(2):113-8.e1-2. doi: 10.1016/j.cllc.2015.09.003. Epub 2015 Oct 23.

48.

Lung-MAP--framework, overview, and design principles.

Ferrarotto R, Redman MW, Gandara DR, Herbst RS, Papadimitrakopoulou VA.

Chin Clin Oncol. 2015 Sep;4(3):36. doi: 10.3978/j.issn.2304-3865.2015.09.02. Review.

49.

Investigation of metabolomic blood biomarkers for detection of adenocarcinoma lung cancer.

Fahrmann JF, Kim K, DeFelice BC, Taylor SL, Gandara DR, Yoneda KY, Cooke DT, Fiehn O, Kelly K, Miyamoto S.

Cancer Epidemiol Biomarkers Prev. 2015 Nov;24(11):1716-23. doi: 10.1158/1055-9965.EPI-15-0427. Epub 2015 Aug 17.

50.

Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy.

Pan CX, Zhang H, Tepper CG, Lin TY, Davis RR, Keck J, Ghosh PM, Gill P, Airhart S, Bult C, Gandara DR, Liu E, de Vere White RW.

PLoS One. 2015 Aug 13;10(8):e0134346. doi: 10.1371/journal.pone.0134346. eCollection 2015.

Supplemental Content

Loading ...
Support Center